One pharmacist drew attention to a massive pricing disparity on a key cancer drug, and that disparity may help to explain why ...
(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...
Many older adults with advanced cancer receive potentially aggressive treatment but not a lot of supportive care, according ...
Around 21 million adults in the U.S. (8.4%) experienced a major depressive episode in 2023 and Medicare Part B recipients are ...
Researchers analyzed 33,744 fee-for-service Medicare decedents with distant-stage breast, prostate, pancreatic, or lung cancers who died between 2014 and 2019.
Millions of American women are at high risk for breast cancer, but their insurance does not cover the costs of extra ...
Members of the Senate Finance Committee have reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, a bipartisan bill that would establish a Medicare Coverage pathway to ...
Several key members of the Senate Finance Committee have reintroduced a bill that seeks to establish a Medicare coverage ...
Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...
In addition to the coverage in NSCLC, Signatera is also covered by Medicare for adjuvant and recurrence monitoring in colorectal cancer, muscle-invasive bladder cancer, breast cancer, and ovarian ...
Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results